| Autor: |
Ritawidya, Rien, Palangka, Citra Rezza Aurora Putri, Humani, Titis Sekar, Susilo, Veronika Yulianti, Darojatin, Ilma, Pujiyanto, Anung |
| Předmět: |
|
| Zdroj: |
Indonesian Journal of Pharmacy / Majalah Farmasi Indonesia; 2022, Vol. 33 Issue 3, p333-352, 20p |
| Abstrakt: |
Somatostatin receptors (SSTRs) are peptide receptors that are overexpressed in a wide variety of cancers including neuroendocrine tumors (NETs). Because of their short biological half-life and low metabolic stability in vivo, natural somatostatin ligands are not suitable for clinical applications. Octreotide is a synthetic somatostatin peptide analog that has been extensively evaluated for the development of SSTR-specific molecular imaging and radionuclide therapy of NETs. In this review, we summarize the development of the radiolabeled octreotide analogs 111In, 99mTc, and 123I for molecular imaging of NETs via single-photon emission computed tomography (SPECT), 68Ga-labeled somatostatin analog for molecular imaging using positron emission tomography (PET), and 177Lu-, 90Y-, and 111In-labeled somatostatin analogs for peptide receptor radionuclide therapy (PRRT) of NETs. Our review of the literature indicates that these radiolabeled somatostatin analogs exhibit good image quality and high tumor uptake and highlight the potential applications of radiolabeled somatostatin analogs for the molecular imaging and targeted treatment of NETs. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
